News

Successful anti-TNF therapy may cancel excess coronary risk in RA


 

AT THE ACR ANNUAL MEETING

The Swedish Biologics Register is funded by the Swedish Rheumatology Association, with support from half a dozen pharmaceutical companies. Dr. Ljung disclosed ties with AbbVie and Bristol-Myers Squibb.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Intervention boosts post-acute coronary syndrome medication adherence, but not outcomes
MDedge Internal Medicine
Anticoagulant edoxaban comparable with warfarin in atrial fib
MDedge Internal Medicine
CORAL: No added benefit with renal stenting vs. medication alone
MDedge Internal Medicine
Varespladib raises MI risk after recent acute coronary syndrome
MDedge Internal Medicine
AHA-ACC experts defend new risk formula in presser
MDedge Internal Medicine
New prevention guidelines bring welcome changes
MDedge Internal Medicine
Abandon LDL targets? Not yet
MDedge Internal Medicine
Guideline authors, AHA-ACC leaders confident in risk calculator
MDedge Internal Medicine
VIDEO: AHA/ACC work group cochair defends, explains risk calculator
MDedge Internal Medicine
TOPCAT: Spironolactone cuts hospitalizations for diastolic heart failure
MDedge Internal Medicine